Exact Mass: 379.0045
Exact Mass Matches: 379.0045
Found 66 metabolites which its exact mass value is equals to given mass value 379.0045,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide
6-Thioguanosine monophosphate
6-Thioguanosine monophosphate is a metabolite of tioguanine. Tioguanine, formerly thioguanine, is a drug that is used in the treatment of cancer. It belongs to the family of drugs called antimetabolites. It is a guanine analog. (Wikipedia) Norcodeine
[2,3-e]-1,2-Thiazine-6-sulfonamide 1,1-Dioxide 1
Cyclopenthiazide
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
[(2R,5R)-5-(2-Amino-6-sulfanylidene-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
Pyridinium-3,5-biscarboxylic acid mononucleotide; P2CMN; Pyridin-1-ium-3,5-dicarboxylate mononucleotide; Pyridinium-3,5-biscarboxylate mononucleotide
cyclopenthiazide
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
((4R,5R)-5-(4-Iodophenyl)-2-phenyl-4,5-dihydrooxazol-4-yl)methanol
N-(p-Hydroxyphenethyl)-N-(2-bromo-5-hydroxy-4-methoxybenzyl)formamide
2-[3-(2,6-dichlorophenyl)sulfanyl-2,5-dimethylindol-1-yl]acetic acid
Ethyl 8-bromo-4-hydroxy-6-(trifluoromethoxy)quinoline-3-carboxylate
2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl [R-(R*,R*)]-aminoacetate
ETHYL 4-(3,5-DICHLOROPHENOXY)-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE
2-(3-BROMO-PHENYL)-6-(4-METHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE
2-[4-(2-phenyl-1,3-thiazol-4-yl)anilino]-1,3-thiazole-4-carboxylic acid
1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-bromo-1-(phenylsulfonyl)-
3-BROMO-1-(4-[5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-1,4-DIAZEPAN-1-YL)PROPAN-1-ONE
L-689,560
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists
4-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one
2-chloro-N-(7-methyl-9-oxo-2-thioxanthenyl)benzamide
3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
3-Bromo-6-Phenyl-N-(Pyrimidin-5-Ylmethyl)imidazo[1,2-A]pyridin-8-Amine
3-Bromo-5-Phenyl-N-(Pyrimidin-5-Ylmethyl)pyrazolo[1,5-A]pyridin-7-Amine
3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
2-Amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one
[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(4-nitrophenoxy)oxan-2-yl]methyl phosphate
5-[(2,4-dichlorophenoxy)methyl]-N-(2-fluorophenyl)furan-2-carboxamide
(2-Chloro-5-nitrophenyl)(4-(3-chlorophenyl)piperazin-1-yl)methanone
2-[[2-(4-Ethoxy-3-methoxyphenyl)-4-thiazolyl]methylthio]-5-methyl-1,3,4-thiadiazole
Methyl 5-chloro-4-{[3-(4-chlorophenyl)acryloyl]amino}-2-methoxybenzoate
N-[(4-sulfamoylanilino)-sulfanylidenemethyl]-1,3-benzodioxole-5-carboxamide
isopropyl 4-{[(4-bromo-1-ethyl-1H-pyrazol-5-yl)carbonyl]amino}benzoate
tetracenomycin D3(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.
methanesulfonic acid [(2R,5R)-2-(6-amino-2-chloro-9-purinyl)-4-hydroxy-5-(hydroxymethyl)-3-oxolanyl] ester
4-chloro-N-(3-hydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide
2-[[3,4-Dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]amino]acetic acid
4-chloro-N-(5-hydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide
4-chloro-N-[(2S)-2-methyl-3-oxo-2H-indol-1-yl]-3-sulfamoylbenzamide
O-304
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications [1][2].
